Nature reviews. Clinical oncology
Journal
Overview
publication venue for
-
Publisher Correction: Lineage plasticity in cancer: a shared pathway of therapeutic resistance.
2020
-
Precision oncology in non-small-cell lung cancer: opportunities and challenges..
15.
2018
-
Radiotherapy: has the role of WBRT in primary CNS lymphoma been settled?.
8.
2011
-
Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'..
16.
2019
-
Small-cell lung cancer in 2016: Shining light on novel targets and therapies..
14.
2016
-
Lung cancer: First-line immunotherapy in lung cancer - taking the first step..
13.
2016
-
Decade in review--genomics: a decade of discovery in cancer genomics..
11.
2014
-
Gastrointestinal cancer: targeted therapies in gastric cancer-the dawn of a new era..
11.
2013
-
Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer..
10.
2013
-
Urological cancer: Time for another rethink on prostate cancer screening..
9.
2011
-
200 mg/m(2) melphalan--the gold standard for multiple myeloma..
7.
2010
-
Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer..
7.
2010
-
The KRYSTAL-1 study of adagrasib - a new trial for KRASG12C-mutated non-small-cell lung cancer.
2022
-
Correction regarding data on blinatumomab-associated seizures.
2016
-
Imaging biomarker roadmap for cancer studies.
2016
-
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.
2020
-
ROS1-dependent cancers - biology, diagnostics and therapeutics.
2020
-
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
2020
-
Towards individualized therapy for metastatic renal cell carcinoma.
2019
-
Emerging epigenetic-modulating therapies in lymphoma.
2019
-
NTRK fusion-positive cancers and TRK inhibitor therapy.
2018
-
Treatment resistance in urothelial carcinoma: an evolutionary perspective.
2018
-
The emerging clinical relevance of genomics in cancer medicine.
2018
-
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
2017
-
Drug development for noncastrate prostate cancer in a changed therapeutic landscape.
2017
-
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.
2017
-
Unravelling the biology of SCLC: implications for therapy.
2017
-
The high price of anticancer drugs: origins, implications, barriers, solutions.
2017
-
Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.
2016
-
Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy.
2016
-
Genomic complexity of multiple myeloma and its clinical implications.
2016
-
Non-invasive metabolic imaging of brain tumours in the era of precision medicine.
2016
-
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
2016
-
Clinical impact of tumour biology in the management of gastroesophageal cancer.
2016
-
Refining the treatment of NSCLC according to histological and molecular subtypes.
2015
-
Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy.
2015
-
Minimal residual disease in multiple myeloma: bringing the bench to the bedside.
2015
-
Precision therapy for lymphoma--current state and future directions.
2014
-
High-risk prostate cancer-classification and therapy.
2014
-
Can we deliver randomized trials of focal therapy in prostate cancer?
2014
-
Lung cancer in 2013: Refining standard practice and admitting uncertainty.
2014
-
Molecular targets on the horizon for kidney and urothelial cancer.
2013
-
Complementary or alternative medicine in cancer care-myths and realities.
2013
-
The future of epigenetic therapy in solid tumours--lessons from the past.
2013
-
Validation and clinical utility of prostate cancer biomarkers.
2013
-
Reducing the toxicity of cancer therapy: recognizing needs, taking action.
2012
-
Exercise rehabilitation in patients with cancer.
2012
-
Prostate cancer in 2011: Hitting old targets better and identifying new targets.
2012
-
Noninvasive cell-tracking methods.
2011
-
The role of local therapy in the management of lung and liver oligometastases.
2011
-
Metastasis-suppressor genes in clinical practice: lost in translation?
2011
-
Conscripts of the infinite armada: systemic cancer therapy using nanomaterials.
2010
-
Stereotactic body radiation therapy: a novel treatment modality.
2009
-
Next generation oncology drug development: opportunities and challenges.
2009
-
BRAF - a tumour-agnostic drug target with lineage-specific dependencies.
2024
-
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
2024
-
Emerging evidence for adapting radiotherapy to immunotherapy.
2023
-
Improving outcomes in patients with oesophageal cancer.
2023
-
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies.
2022
-
Clinical implications of T cell exhaustion for cancer immunotherapy.
2022
-
Is early-onset cancer an emerging global epidemic? Current evidence and future implications.
2022
-
Radiotheranostics in oncology: current challenges and emerging opportunities.
2022
-
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.
2022
-
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.
2021
-
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.
2021
-
Immunogenicity of CAR T cells in cancer therapy.
2021
-
Unlocking the potential of antibody-drug conjugates for cancer therapy.
2021
-
Lineage plasticity in cancer: a shared pathway of therapeutic resistance.
2020
-
Engineering strategies to overcome the current roadblocks in CAR T cell therapy.
2019
-
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.
2019
-
Counselling framework for moderate-penetrance cancer-susceptibility mutations.
2016
-
Population-based screening for cancer: hope and hype.
2016
-
Driving CAR T-cells forward.
2016
-
Molecular therapy for acute myeloid leukaemia.
2015
-
Novel immunotherapies in lymphoid malignancies.
2015
-
Cancer-treatment-induced neurotoxicity--focus on newer treatments.
2015
-
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.
2015
-
Current management of lesions associated with an increased risk of breast cancer.
2015
-
The inverted pyramid of biomarker-driven trials.
2011
-
Clinical implications of cancer self-seeding.
2011
-
Molecular mechanisms of metastasis in breast cancer--clinical applications.
2010
-
Molecular targets for treatment of inflammatory breast cancer.
2009
Identity
ISO Abbreviation
Linking ISSN
Electronic International Standard Serial Number (EISSN)